Novartis Lines Up $1 Billion For China R&D
This article was originally published in PharmAsia News
Executive Summary
Novartis announced Nov. 3 a five-year, $1 billion investment in China, upping the ante for multinationals trying to build strong foundations in China's burgeoning R&D space
You may also be interested in...
Novartis Replaces China President With Hewlett-Packard VP For Government Affairs, Gearing Up For Growth
To drive China growth, the Swiss pharma giant announced a change in leadership in China as former Wyeth/Pfizer government affairs expert, Ms. Xu Haiying takes reigns as new China president.
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.
After Januvia And Onglyza, Novartis Launches Galvus In China; Lucentis Receives SFDA Nod
Novartis looks to take on Merck’s Januvia in China, noting it will have a level-playing field despite playing catch up in the market with the world’s largest diabetes population.